iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report)’s share price hit a new 52-week high on Thursday . The stock traded as high as $94.89 and last traded at $93.34, with a volume of 47710 shares. The stock had previously closed at $93.79.
iShares U.S. Pharmaceuticals ETF Stock Down 0.5%
The company has a market cap of $1.01 billion, a P/E ratio of 17.75 and a beta of 0.50. The firm’s 50 day moving average is $88.77 and its two-hundred day moving average is $87.38.
Institutional Trading of iShares U.S. Pharmaceuticals ETF
Institutional investors have recently modified their holdings of the business. Stratos Wealth Advisors LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the fourth quarter worth $555,000. Accurate Wealth Management LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at $6,372,000. D.A. Davidson & CO. bought a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at $1,709,000. Childress Capital Advisors LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at $1,018,000. Finally, Anfield Capital Management LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at $10,007,000.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
